Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer Interventions: Drug: Zumsemetinib; Drug: Capecitabine; Drug: Zoledronic acid; Drug: Denosumab Sponsors: Washington University School of Medicine; United States Department of Defense; Aclaris Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials